RE:RE:Domino Effect and f German Legalization Faltischek told Benzinga that "of particular importance to Tilray is the adoption of the new Medical Cannabis Act, MedCanG, which provides de-scheduling of cannabis as a narcotic, which we expect will significantly expand the medical cannabis market in Germany allowing for wider insurance coverage as well as enhanced accessibility to high-quality cannabis for medical patient."
Tilray Brand's medical division, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments, in over 20 countries and across five continents. It grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Recently, senior analyst Pablo Zuanic of Zuanic & Associates called Tilray one of the better-positioned companies to benefit from the country's new cannabis policy.
Faltischek said the company looks forward to exploring the path opened by the German government, promoting improved access to medical marijuana and optimizing care for its patients.